Fluoroscopic Guided Interlaminar Epidural Versus Ultrasound Guided Transforaminal Epidural in the Treatment of Unilateral Cervicobrachialgia.

Sponsor
Centre Hospitalier Universitaire Saint Pierre (Other)
Overall Status
Unknown status
CT.gov ID
NCT04475445
Collaborator
(none)
60
1
2
11
5.4

Study Details

Study Description

Brief Summary

Chronic cervicobrachialgia is a public health problem. Epidural injections of corticosteroids and local anesthesics via transforaminal and interlaminar routes both have shown their potential in its treatment. The interlaminar approach offers the advantage of an epidural injection (i.e., direct contact with the nerve root in the epidural space). However, it requires fluoroscopy and can lead to potentially serious complications (compression of the nerve root, spinal cord injury...). The ultrasound-guided injection of corticosteroids via the transforaminal route, which offers the advantage of selectively targeting the symptomatic nerve root, may have the same therapeutic advantages as the interlaminar approach in decreasing unilateral cervicobrachial pain (i.e. a decrease in pain after infiltration) and reduce its risks.The aim of this study is to compare the efficacy of transforaminal vs interlaminar cervical corticosteroid injection.

Condition or Disease Intervention/Treatment Phase
  • Other: Ultrasound-guided transforaminal epidural steroid injection
  • Other: Interlaminar epidural steroid injection
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Fluoroscopic Guided Interlaminar Epidural Versus Ultrasound Guided Transforaminal Epidural in the Treatment of Unilateral Cervicobrachialgia : a Randomized Controlled Trial
Actual Study Start Date :
Jul 30, 2020
Anticipated Primary Completion Date :
Jul 1, 2021
Anticipated Study Completion Date :
Jul 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ultrasound guided transforaminal epidural steroid injection

Other: Ultrasound-guided transforaminal epidural steroid injection
Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.

Experimental: Interlaminar epidural steroid injection

Other: Interlaminar epidural steroid injection
Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.

Outcome Measures

Primary Outcome Measures

  1. Visual Analogue Score change at 30 minutes post infiltration when compared to baseline [up to 30 minutes]

    Pain will be evaluated by Visual Analog Scale (VAS) before and 30 minutes after corticosteroid infiltration. Visual Analog pain score (scale = 0 no pain; 10= worst pain imaginable)

Secondary Outcome Measures

  1. Visual Analogue Score change at 1 month post infiltration when compared to baseline [up to 1 month]

    Pain will be evaluated by Visual Analog Scale (VAS) before and 1 month after corticosteroid infiltration. Visual Analog pain score (scale = 0 no pain; 10= worst pain imaginable)

  2. Patient satisfaction during procedure [at the end of infiltration]

    Pain will be evaluated by Satisfaction scale after procedure (0= unsatisfied, 5= very satisfied)

  3. Neck disability index (NDI) score (questionnaire) [up to 1 month]

    Neck disability index (NDI) score will be calculated before, 30 minutes and 1 month after corticosteroid infiltration The NDI is a standard instrument for measuring self-rated disability due to neck pain. Each of the 10 items is scored from 0 - 5. The maximum score is therefore 50. Points summed to a total score. The test can be interpreted as a raw score, with a maximum score of 50, Interpretation for scoring intervals : 0 - 4 = no disability; 5 - 14 = mild disability; 15 - 24 = moderate disability; 25 - 34 = severe disability, above 34 = complete disability.

  4. Rate of Procedure failure [up to 30 minutes]

    The procedure will be considered as a failure if the infiltration is not performed.

  5. Incidence of Adverse effects (lipothymia, nausea, vomiting) [up to 1 month]

  6. Incidence of complications (stroke, hematoma, paralysis) [up to 1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiologists physical status (ASA) I-III

  • Chronic unilateral cervicobrachial pain

  • Allowed Steroid infiltration

Exclusion Criteria:
  • Pregnancy

  • Lactation

  • Allergy or intolerance to any of the drugs/materials used in this study,

  • Participation in another interventional study

  • Systemic anticoagulation,

  • Infection at the puncture site

  • Patient refusal.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Saint-Pierre Bruxelles Belgium 1000

Sponsors and Collaborators

  • Centre Hospitalier Universitaire Saint Pierre

Investigators

  • Study Director: Panayota Kapessidou, MD,PhD, University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)
  • Principal Investigator: Mohamed Ali Bali, MD, mohamed_bali@stpierre-bru.be

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier Universitaire Saint Pierre
ClinicalTrials.gov Identifier:
NCT04475445
Other Study ID Numbers:
  • CE/20-04-08
First Posted:
Jul 17, 2020
Last Update Posted:
Aug 19, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire Saint Pierre
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2020